Recent studies suggest that decapeptide-12 was 17-fold more potent than hydroquinone at inhibiting tyrosinase in vitro. .
[15] This study also showed that decapeptide-12 was not cytotoxic to melanocytes, making it a safer alternative to hydroquinone. A pilot study by Hantash and Jimenez showed that twice a day treatment for 4 months with decapeptide-12 formulated in a topical emulsion also resulted in a 50% improvement in melasma in patients who had failed 6 months of Tri-Luma therapy.
[16] The potential of decapeptide-12 as a therapeutic option for melasma was recently reviewed.
[17]